In vivo brain microdialysis to evaluate FITC-dextran encapsulated immunopegylated nanoparticles

Drug Delivery

Volumn 19, Issue 6, 2012, Pages 298-306

  Bommana, Murali Mohan ^a   Kirthivasan, Bharat ^a   Squillante, Emilio ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Brain targeting; Confocal microscopy; Fluorescence microscopy; OX26; Pegylation; Permeability marker

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE DEXTRAN; MALEIMIDE POLY(ETHYLENE GLYCOL) POLY(LACTIDE) NANOPARTICLE; METHOXY POLY(ETHYLENE GLYCOL) POLY(LACTIDE) NANOPARTICLE; NANOPARTICLE; PARAFORMALDEHYDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; RAT; ZETA POTENTIAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BLOOD-BRAIN BARRIER; BRAIN; DEXTRANS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; MALE; MALEIMIDES; MICRODIALYSIS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; RATS; RECEPTORS, TRANSFERRIN; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84866256059     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.714812     Document Type: Article

References (32)

1. Abbott NJ. (2005). Physiology of the blood brain barrier and its consequences for drug transport to the brain. Int Congr Ser 1277:3-18 (Pubitemid 43693341)
2. Aktas Y, Yemisci M, Andrieux K, Gürsoy RN, Alonso MJ, Fernandez-Megia E, Novoa-Carballal R, Quiñoá E, Riguera R, Sargon MF, Celik HH, Demir AS, Hincal AA, Dalkara T, Capan Y, Couvreur P. (2005). Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26 Bioconjug Chem 16:1503-1511 (Pubitemid 41681517)
3. Aliautdin RN, Petrov VE, Ivanov AA, Kreuter J, Kharkevich DA. (1996). [Transport of the hexapeptide dalargin across the hematoencephalic barrier into the brain using polymer nanoparticles]. Eksp Klin Farmakol 59:57-60
4. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. (1997). Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 14:325-328 (Pubitemid 27160944)
5. Ballabh P, Braun A, Nedergaard M. (2004). The blood-brain barrier: an overview: Structure, regulation, and clinical implications. Neurobiol Dis 16:1-13 (Pubitemid 38569790)
6. Béduneau A, Saulnier P, Hindré F, Clavreul A, Leroux JC, Benoit JP. (2007). Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. Biomaterials 28:4978-4990 (Pubitemid 47371148)
7. Blackburn-Munro G, Jensen BS. (2003). The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 460:109-116 (Pubitemid 36139977)
8. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. (2007). Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 59:454-477 (Pubitemid 47259226)
9. Boschi G, Scherrmann J. (2000). Microdialysis in mice for drug delivery research. Adv Drug Deliv Rev 45:271-281
10. Das D, Lin S. (2005). Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J Pharm Sci 94:1343-1353 (Pubitemid 40904197)
11. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. (2005). Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm 298:274-292 (Pubitemid 40910731)
12. Gelperina S, Maksimenko O, Khalansky A, Vanchugova L, Shipulo E, Abbasova K, Berdiev R, Wohlfart S, Chepurnova N, Kreuter J. (2010). Drug delivery to the brain using surfactant-coated poly(lactide-coglycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 74:157-163
13. Giustini AJ, Ivkov R, Hoopes PJ. (2011). Magnetic nanoparticle biodistribution following intratumoral administration. Nanotechnology 22:345101
14. Hoffmann A, Bredno J, Wendland M, Derugin N, Ohara P, Wintermark M. (2011). High and Low Molecular Weight Fluorescein Isothiocyanate (FITC)-Dextrans to Assess Blood-Brain Barrier Disruption: Technical Considerations. Transl Stroke Res 2:106-111
15. Kim HR, Gil S, Andrieux K, Nicolas V, Appel M, Chacun H, Desmaële D, Taran F, Georgin D, Couvreur P. (2007). Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol Life Sci 64:356-364 (Pubitemid 46440206)
16. Kirthivasan B, Singh D, Bommana MM, Raut SL, Squillante E, Sadoqi M. (2012). Active brain targeting of a fluorescent P-gp substrate using polymeric magnetic nanocarrier system. Nanotechnology 23:255102
17. Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65-81 (Pubitemid 32209233)
18. Kreuter J. (2005). Application of nanoparticles for the delivery of drugs to the brain. Int Congr Ser 1277:85-94 (Pubitemid 43693337)
19. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. (1995). Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674:171-174
20. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. (1997). Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood brain barrier using surfactant-coated nanoparticles. J Control Release 49:81-87 (Pubitemid 27417903)
21. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 10:317-325 (Pubitemid 34746313)
22. Moos T, Morgan EH. (2001). Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat. J Neurochem 79:119-129 (Pubitemid 32946649)
23. Olivier JC. (2005). Drug transport to brain with targeted nanoparticles. NeuroRx 2:108-119
24. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. (2002). Synthesis of pegylated immunonanoparticles. Pharm Res 19:1137-1143 (Pubitemid 34984997)
25. Pardridge WM. (2005). The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3-14 (Pubitemid 40128022)
26. Parikh T, Bommana MM, Squillante E 3rd. (2010). Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain. Eur J Pharm Biopharm 74:442-450
27. Paxinos G, Watson C. (1986). The rat brain in stereotaxic coordinates. Sydney; Orlando: Academic Press.
28. Raut SL, Kirthivasan B, Bommana MM, Squillante E, Sadoqi M. (2010). The formulation, characterization and in vivo evaluation of a magnetic carrier for brain delivery of NIR dye. Nanotechnology 21:395102
29. Storm G, Belliot SO, Daemen T, Lasic DD. (1995). Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 17:31-48
30. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. (2009). Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 71:251-256
31. Vaka SR, Sammeta SM, Day LB, Murthy SN. (2009). Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci 98:3640-3646
32. van Rooy I, Cakir-Tascioglu S, Hennink WE, Storm G, Schiffelers RM, Mastrobattista E. (2011). In vivo methods to study uptake of nanoparticles into the brain. Pharm Res 28:456-471.